CompoAtlas

Vitaldin Aswagandha Gummies

Food supplement declared in France, declaration No 2022-2-984

Vitaldin Aswagandha Gummies, from Boston Nutraceutical Science S.L., is a food supplement declared in France. Status: withdrawn from the market on 29 August 2025. Main ingredients: Withania somnifera 300 mg per day, Sodium, Vitamin D. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
Vitaldin
Food business operator placing the product on the market
Boston Nutraceutical Science S.L.
Status
Withdrawn from the market on 29 August 2025
Form
Gummy
Daily dose
2 gummies
Directions for use
Prende 2 pièces par jour
Not recommended (according to the manufacturer)
Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Taking thyroid medication

Declaration 318629, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Withania somnifera (L.) DunalRacineExtrait sec aqueux300 mg

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
sodium citrateSodiumno limit (insufficient data)no fixed dose
ergocalciferolVitamin D100 µg (4,000 IU)5 µg (200 IU)

Additives

E330, E270, E440, E903

Other ingredients

sirop de glucose, sucre, eau, huile de palme

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Ne dépassez pas la dose quotidienne expressément recommandée. Les compléments alimentaires ne se substitue pas à une alimentation variée et équilibrée et à un mode de vie sain. Conserver hors de la portée des jeunes enfants. NON RECOMMANDÉ AUX ENFANTS. Non recommandé aux femmes enceintes, allaitantes ou aux personnes souffrant de troubles de la thyroïde.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Withania somnifera (L.) Dunal
    Read the warning, when it applies and the studies cited

    ASHWAGANDHA - WITHANIA SOMNIFERA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).

    Sources cited by Health Canada (3)
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
    • Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.

    Health Canada monograph dated 28 February 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : Vitaldin

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Vitaldin Aswagandha Gummies: composition and regulation”, https://compoatlas.com/en/supplements/products/318629-vitaldin-aswagandha-gummies, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line